Everolimus-Facilitated Reduction Of Tacrolimus Provides Comparable Efficacy And Superior Renal Function Versus Standard Tacrolimus In De Novo Liver Transplant Recipients: 24-Month Results Of A Randomized Trial

被引：0
|
作者：
Saliba, Faouzi [1 ]
De Simone, Paolo [2 ]
Nevens, Frederik [3 ]
De Carlis, Luciano [4 ]
Metselaar, Herold [5 ]
Beckebaum, Susanne [6 ]
Jonas, Sven [7 ]
Sudan, Debra [8 ]
Fischer, Lutz [9 ]
Fung, John J. [10 ]
Dong, Gaohong [11 ]
Lopez, Patricia M. [12 ]
Junge, Guido [12 ]
机构：
[1] Hop Paul Brousse, Villejuif, France
[2] Azienda Osped Univ Pisana, Pisa, Italy
[3] Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Louvain, Belgium
[4] Osped Niguarda Ca Granda, Milan, Italy
[5] Univ Rotterdam Hosp, Erasmus MC, Rotterdam, Netherlands
[6] Univ Hosp Essen, Essen, Germany
[7] Univ Med Ctr Leipzig, Leipzig, Germany
[8] Duke Univ, Med Ctr, Durham, NC USA
[9] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[10] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[11] Novartis Pharmaceut, E Hanover, NJ USA
[12] Novartis Pharma AG, Basel, Switzerland
来源：
HEPATOLOGY | 2012年 / 56卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
LB5
引用
收藏
页码：1519 / 1519
页数：1
相关论文
共 50 条
  • [31] Efficacy and Safety of Everolimus with Early Reduction or Elimination of Tacrolimus in 719 de Novo Liver Transplant Recipients - Results at 12 Months
    De Simone, P.
    Nevens, F.
    Duvoux, C.
    Koneru, B.
    McCormack, L.
    McCaughan, G.
    Navasa, M.
    Dong, G.
    Hexham, J. M.
    Junge, G.
    Fung, J.
    TRANSPLANTATION, 2012, 94 (10) : 750 - 750
  • [32] RANDOMIZED, MULTICENTER STUDY OF EVEROLIMUS WITH EARLY REDUCTION OR ELIMINATION OF TACROLIMUS IN 719 DE NOVO LIVER TRANSPLANT RECIPIENTS: RESULTS AT 12 MONTHS
    Saliba, Faouzi
    Duvoux, Christophe
    Durand, Francois
    Neau-Cransac, Martine
    Hardwigsen, Jean
    Pageaux, Georges
    Boleslawski, Emmanuel
    TRANSPLANT INTERNATIONAL, 2012, 25 : 39 - 39
  • [33] Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data
    Qazi, Y.
    Shaffer, D.
    Kaplan, B.
    Kim, D. Y.
    Luan, F. L.
    Peddi, V. R.
    Shihab, F.
    Tomlanovich, S.
    Yilmaz, S.
    McCague, K.
    Patel, D.
    Mulgaonkar, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 (05) : 1358 - 1369
  • [34] Improvement of renal function with everolimus plus reduced tacrolimus in de novo liver transplant recipients - HEPHAISTOS study 12 month data.
    Schlitt, H. J.
    Nashan, B.
    Braun, F.
    Pascher, A.
    Klein, C. -G
    Neumann, U.
    Kroeger, I
    Wimmer, P.
    Schemmer, P.
    TRANSPLANTATION, 2019, 103 (08) : 46 - 46
  • [35] EARLY TACROLIMUS WITHDRAWAL AFTER LIVER TRANSPLANTATION PROVIDES IMPROVEMENT OF RENAL FUNCTION VS. EVEROLIMUS-FACILITATED REDUCED-EXPOSURE TACROLIMUS: RESULTS OF A NATIONAL PILOT STUDY
    De Simone, Paolo
    Tisone, Giuseppe
    Di Benedetto, Fabrizio
    Pinna, Antonio Daniele
    Tedeschi, Umberto
    Baccarani, Umberto
    Lupo, Luigi Giovanni
    Fagiuoli, Stefano
    Cillo, Umberto
    TRANSPLANT INTERNATIONAL, 2017, 30 : 66 - 66
  • [36] The H2304E1 Study: Efficacy and Safety of Everolimus With Reduced Tacrolimus Versus Standard Tacrolimus in De Novo Liver Transplant Recipients at 36 Months.
    De Simone, P.
    Kaiser, G. M.
    De Carlis, L.
    Metselaar, H. J.
    Duvoux, C.
    Nevens, F.
    Fischer, L.
    Fung, J.
    Dong, G.
    Rauer, B.
    Junge, G.
    Saliba, F.
    LIVER TRANSPLANTATION, 2014, 20 : S106 - S106
  • [37] Efficacy and safety of everolimus in combination with reduced tacrolimus in de novo liver transplant recipients: 36-month results from the randomized H2304 study
    Saliba, Faouzi
    Kaiser, Gernot M.
    De Carlis, Luciano
    Metselaar, Herold J.
    De Simone, Paolo
    Duvoux, Christophe
    Nevens, Frederik
    Fischer, Lutz
    Fung, John J.
    Dong, Gaohong
    Rauer, Barbara
    Junge, Guido
    HEPATOLOGY, 2013, 58 (06) : 1383A - 1383A
  • [38] EFFECT OF TACROLIMUS EXPOSURE ON EVEROLIMUS-BASED IMMUNOSUPPRESSION IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS: A 24-MONTH ANALYSIS FROM TRANSFORM STUDY
    Citterio, Franco
    Peddi, V. Ram
    Qazi, Yasir
    Kim, Dean
    Vincenti, Flavio
    Berger, Stefan
    Sommerer, Claudia
    Gawai, Apurva
    Hernandez-Gutierrez, Maria-Pilar
    Bernhardt, Peter
    Oberbauer, Rainer
    TRANSPLANT INTERNATIONAL, 2021, 34 : 254 - 255
  • [39] EFFICACY AND SAFETY OF EVEROLIMUS IN COMBINATION WITH REDUCED TACROLIMUS IN DE NOVO LIVER TRANSPLANT RECIPIENTS: 36-MONTH RESULTS FROM THE RANDOMIZED H2304 STUDY
    Saliba, F.
    Duvoux, C.
    Durand, F.
    Neau-Cransac, M.
    Hardwigsen, J.
    Pageaux, G.
    Di Giambattista, F.
    TRANSPLANT INTERNATIONAL, 2015, 28 : 18 - 18
  • [40] An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients
    Sommerer, Claudia
    Suwelack, Barbara
    Dragun, Duska
    Schenker, Peter
    Hauser, Ingeborg A.
    Witzke, Oliver
    Hugo, Christian
    Kamar, Nassim
    Merville, Pierre
    Junge, Martina
    Thaiss, Friedrich
    Nashan, Bjoern
    Almartine, Eric
    Dantal, Jacques
    Dragun, Duska
    Feldkamp, Thorsten
    Hauser, Ingeborg A.
    Hazzan, Marc
    Heyne, Nils
    Hugo, Christian
    Kamar, Nassim
    Lang, Philippe
    Lehner, Frank
    Le Meur, Yannick
    Lutz, Jens
    Merville, Pierre
    Morelon, Emmanuel
    Moulin, Bruno
    Mousson, Christiane
    Muehlfeld, Anja
    Nashan, Bjorn
    Pisarski, Przemyslaw
    Rondeau, Eric
    Schenker, Peter
    Sommerer, Claudia
    Suwelack, Barbara
    Thaiss, Friedrich
    Thierry, Antoine
    Wiesener, Michael
    Witzke, Oliver
    KIDNEY INTERNATIONAL, 2019, 96 (01) : 231 - 244
12345